Current anti-vascular endothelial growth factor (VEGF) therapies have revolutionized treatment for the inhibition of the pathological neoangiogenesis of wet AMD (advanced disease), however, many years after the progression of degeneration has ensued [8, 9]. This evidence concerns the gene VEGFA and wet macular degeneration.